share_log

Zhejiang Jingxin Pharmaceutical (SZSE:002020) Strong Profits May Be Masking Some Underlying Issues

Zhejiang Jingxin Pharmaceutical (SZSE:002020) Strong Profits May Be Masking Some Underlying Issues

京新藥業(SZSE:002020)盈利強勁,可能掩蓋了一些潛在問題
Simply Wall St ·  2024/11/01 06:15

Zhejiang Jingxin Pharmaceutical Co., Ltd.'s (SZSE:002020) healthy profit numbers didn't contain any surprises for investors. We believe that shareholders have noticed some concerning factors beyond the statutory profit numbers.

浙江京新藥業(SZSE:002020)的盈利數字對投資者並沒有什麼意外。我們認爲股東們已經注意到了一些超出法定盈利數字的令人擔憂因素。

big
SZSE:002020 Earnings and Revenue History October 31st 2024
SZSE:002020 盈利和營業收入歷史數據爲2024年10月31日

How Do Unusual Items Influence Profit?

非常規項目如何影響利潤?

Importantly, our data indicates that Zhejiang Jingxin Pharmaceutical's profit received a boost of CN¥119m in unusual items, over the last year. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. Which is hardly surprising, given the name. If Zhejiang Jingxin Pharmaceutical doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

重要的是,我們的數據顯示,浙江京新藥業的盈利在過去一年中由於飛凡項目獲得了CN¥11900萬的提升。雖然我們樂於看到利潤增長,但當飛凡項目做出重大貢獻時,我們往往會更加謹慎。當我們分析全球上市公司的絕大部分時,我們發現重大的飛凡項目通常不會重複出現。這一點並不奇怪,考慮到其名稱。如果浙江京新藥業不再看到該貢獻重複,那麼其他一切不變的情況下,我們預計其利潤在當前年度會下降。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓您想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看基於其估計的未來盈利能力的互動圖表。

Our Take On Zhejiang Jingxin Pharmaceutical's Profit Performance

我們對浙江京新藥業的盈利表現的看法

We'd posit that Zhejiang Jingxin Pharmaceutical's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Because of this, we think that it may be that Zhejiang Jingxin Pharmaceutical's statutory profits are better than its underlying earnings power. The good news is that, its earnings per share increased by 9.1% in the last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. While it's really important to consider how well a company's statutory earnings represent its true earnings power, it's also worth taking a look at what analysts are forecasting for the future. At Simply Wall St, we have analyst estimates which you can view by clicking here.

我們認爲京新藥業的法定收益並不是對持續生產力的清晰衡量,因爲存在大額飛凡項目。因此,我們認爲京新藥業的法定利潤可能比其潛在盈利能力更好。好消息是,其每股收益在過去一年增長了9.1%。歸根結底,如果您想正確了解公司,重要的是考慮不止上述因素。雖然重要的是考慮公司的法定收益如何代表其真實盈利能力,但也值得看看分析師對未來的預測。在Simply Wall St,我們有分析師預測,您可以點擊這裏查看。

Today we've zoomed in on a single data point to better understand the nature of Zhejiang Jingxin Pharmaceutical's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

今天,我們將焦點放在一個單一數據點上,以更好地了解京新藥業利潤的性質。但有很多其他方法可以幫助您了解一家公司。例如,許多人將股本回報率視爲有利的業務經濟指標,而其他人則喜歡『跟隨資金』,搜索內部人員正在買入的股票。雖然您可能需要進行一點研究,但您可能會發現這個免費收集的公司擁有高股本回報率,或者這個擁有重要內部持股的股票清單很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論